Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

Well, with a p-value of <0.001 being credited to the p2 data, doesn’t voclosporin deserve to get a 99% chance of being successful in the p3 trial? If they got that p-value in the p2 data and then try to improve the p3 blender and put the same fruits in the same order as the p2 protocol to get the same results juice, I think it is a very sound argument that the p3 data will also be stellar if not better..UNLESS OF COURSE THE P2 DATA IS A FAUX DATA or MANIPULATED DATA, in which case the management will be in big trouble. Can anybody give me any argument as to why P3 would fail given all the things we know? I can’t find one unless maybe all the patients in p3 are ETs with LN.....just my 2 cents.